Elad Sharon: One of my favorite recent efforts from the SWOG Cancer Research Network’s DART trial – a look at linear change in tumor size
Elad Sharon, Clinical and Translational Director at Dana-Farber Cancer Institute, shared JNCI’s (Journal of the National Cancer Institute) post on X:
“One of my favorite recent efforts from the SWOG Cancer Research Network DART trial involves this look at linear change in tumor size, with excellent correlation with PFS and OS! This could be a more efficient way to evaluate patient benefit, on a trial level, than PFS. Correlation with OS is promising!”
Quoting JNCI’s post about a recent paper by Megan Othus et al. titled “Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial” published in JNCI.
Authors: Megan Othus, Sandip Patel, Young Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
“Study reports linear correlation between tumor size change with PFS and OS in cohort of patients with rare cancers who received immunotherapy.”
Source: Elad Sharon/X and JNCI/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023